MMP9 and cancer: Combination of EGCG and Dacarbazine enhanced the efficacy of Dacarbazine by inhibiting activities of FAK and MMP-9, as well as proliferation and/or metastasis of cancer cells, in which the effective dosage of Dacarbazine was reduced, resulting in less potential cytotoxicity to the healthy cells (204).